8-K: BIO-key International Regains Nasdaq Listing; Trading Resumes

BIO-key International announced its common stock will resume trading on the Nasdaq Capital Market on July 8, 2026, after regaining compliance with listing standards.

Summary

• BIO-key International, Inc. has been notified by Nasdaq that its common stock will resume trading on the Nasdaq Capital Market effective July 8, 2026.
• The company regained compliance with Nasdaq's continued listing standards, including minimum bid price and SEC filing requirements, following a hearing on June 16, 2026.
• BIO-key will be subject to a Discretionary Panel Monitor for one year, until July 6, 2027.
• The company's CEO expressed gratitude to Nasdaq and anticipates significantly improved business results in the current year.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as regaining Nasdaq listing is critical for investor confidence and market access, although the one-year monitoring period introduces a minor cautionary note.

Positives

• Regained compliance with Nasdaq listing standards, allowing trading to resume.
• The company has a growing base of recurring revenue.
• There is expanding interest in BIO-key's biometric technology for cybersecurity.
• BIO-key reports a solid financial position and a streamlined cost structure.
• Management expects significantly improved business results in the current year.

Negatives

• The company will be subject to a Discretionary Panel Monitor for one year until July 6, 2027.

Risks

• The company is subject to risks and uncertainties that may cause actual results to differ materially from forward-looking statements, as detailed in its Form 10-K for the year ended December 31, 2025, and other SEC filings.

Future Outlook

Management expects the company's business to deliver significantly improved results in the current year.

Management Comments

• "We are grateful to Nasdaq and the Hearings Panel for working with us through this process to successfully restore our shares to Nasdaq trading."
• "We have built a growing base of recurring revenue, expanding interest in our biometric technologys ability to solve pervasive cybersecurity vulnerabilities, a solid financial position, and a streamlined cost structure."
• "It is an exciting moment for BIO-key as we expect our business to deliver significantly improved results this year."

Industry Context

StockSavvy.ai notes that BIO-key's successful reinstatement on Nasdaq, following compliance with listing standards, is a positive development in the competitive Identity and Access Management (IAM) and cybersecurity sector, where regaining market confidence is crucial.

Corporate Governance

Stakeholder Impact

• Shareholders: Resumption of trading on Nasdaq is expected to improve liquidity and investor confidence.
• Employees: Positive business outlook and regained listing may boost morale and job security.
• Creditors: Improved financial position and market access could strengthen the company's ability to meet its obligations.

Next Steps

• Trading of BIO-key's common stock to recommence on the Nasdaq Capital Market effective with markets opening on Wednesday, July 8, 2026.
• Company will be subject to a Discretionary Panel Monitor for a period of one year until July 6, 2027.

Key Dates

Recommendation

While the resumption of trading on Nasdaq is a significant positive, the one-year monitoring period and the need for management to deliver on 'significantly improved results' warrant a cautious 'hold' until sustained performance is demonstrated.

Keywords

BIO-key International, Nasdaq, Listing Compliance, Biometric Authentication, Identity and Access Management, Cybersecurity, BKYI, Form 8-K